Dated as of April 30, 2020
Since December 31, 2019 through the date of this Agreement there has not been any Material Adverse Effect.Section 3.07    Legal Proceedings.
(e)    Any attempted Transfer in violation of this Section 5.08 shall be null and void ab initio.Section 5.09    Legend.
(b)    Upon the occurrence of the Advisor Board Seat Fall-Away, the Advisor Director shall immediately resign, and the Investor Parties shall cause the Advisor Director immediately to resign, from the Board effective as of the date of the Advisor Board Seat Fall-Away, and the Investor Parties shall no longer have any rights under this Section 5.10 with respect to the Advisor Director, including, for the avoidance of doubt, any designation and/or nomination rights with respect to the Advisor Director under Section 5.10(c).
Upon the occurrence of the Investor Board Seat Fall-Away, the Investor Director shall immediately resign, and the Investor Parties shall cause the Investor Director immediately to resign, from the Board effective as of the date of the Investor Board Seat Fall-Away, and the Investor Parties shall no longer have any rights under this Section 5.10, including, for the avoidance of doubt, any designation and/or nomination rights under Section 5.10(c)(c)    Until the occurrence of the Advisor Board Seat Fall-Away, at any annual meeting of the Company’s stockholders at which the term of the Advisor Director shall expire, the Investor shall have the right to designate, in accordance with the Company Charter Documents and the DGCL, one Advisor Director.
(d)    In the event of the death, disability, resignation or removal of the Investor Director or the Advisor Director as a member of the Board (in each case other than resignation pursuant to Section 5.10(b)), the Investor may designate an Investor Designee to replace such Investor Director or such Advisor Director, as applicable, and, subject to Section 5.10(e), the Company shall cause such Investor Designee to fill such resulting vacancy.
This Agreement may be terminated and the Transactions abandoned at any time prior to the Closing: 34
(a)    by the mutual written consent of the Company and the Investor;(b)    by either the Company or the Investor upon written notice to the other, if the Closing has not occurred on or prior to July 31, 2020 (the “Termination Date”); provided that the right to terminate this Agreement under this Section 7.01(b) shall not be available to any party if the breach by such party of its representations and warranties set forth in this Agreement or the failure of such party to perform any of its obligations under this Agreement has been a principal cause of or resulted in the events specified in this Section 7.01(b);(c)    by either the Company or the Investor if any Restraint enjoining or otherwise prohibiting consummation of the Transactions shall be in effect and shall have become final and nonappealable; provided that the party seeking to terminate this Agreement pursuant to this Section 7.01(c) shall have used the required efforts to cause the conditions to Closing to be satisfied in accordance with Section 5.02;(d)    by the Investor if the Company shall have breached any of its representations or warranties or failed to perform any of its covenants or agreements set forth in this Agreement, which breach or failure to perform (i) would give rise to the failure of a condition set forth in Section 6.03(a) or Section 6.03(b) and (ii) is incapable of being cured prior to the Termination Date, or if capable of being cured, shall not have been cured within thirty (30) calendar days (but in no event later than the Termination Date) following receipt by the Company of written notice of such breach or failure to perform from the Investor stating the Investor’s intention to terminate this Agreement pursuant to this Section 7.01(d) and the basis for such termination; provided that the Investor shall not have the right to terminate this Agreement pursuant to this Section 7.01(d) if the Investor is then in material breach of any of its representations, warranties, covenants or agreements hereunder; or(e)    by the Company if the Investor shall have breached any of its representations or warranties or failed to perform any of its covenants or agreements set forth in this Agreement, which breach or failure to perform (i) would give rise to the failure of a condition set forth in Section 6.02(a) or Section 6.02(b) and (ii) is incapable of being cured prior to the Termination Date, or if capable of being cured, shall not have been cured within thirty (30) calendar days (but in no event later than the Termination Date) following receipt by the Investor of written notice of such breach or failure to perform from the Company stating the Company’s intention to terminate this Agreement pursuant to this Section 7.01(e) and the basis for such termination; provided that the Company shall not have the right to terminate this Agreement pursuant to this Section 7.01(e) if the Company is then in material breach of any of its representations, warranties, covenants or agreements hereunder.Section 7.02    Effect of Termination.
In the event of the termination of this Agreement as provided in Section 7.01, written notice thereof shall be given to the other party, specifying the provision hereof pursuant to which such termination is made, and this Agreement shall forthwith become null and void (other than Article I, Section 5.05, this Section 7.02 and Article VIII, all of which shall survive termination of this Agreement), and there shall be no liability on the part of the Investor or the Company or their respective directors, officers and Affiliates, except that no such termination shall relieve any party from liability for damages to another party resulting from a knowing or intentional breach of this Agreement or from Fraud.
(d)    No Adjustment.
Control) defaults in making the redemption payment on the applicable redemption date, on and after the redemption date, (A) Accrued Dividends shall cease to accrue on the shares of Series A Preferred Stock so called for redemption; (B) all shares of Series A Preferred Stock called for redemption shall no longer be deemed outstanding; and (C) all rights with respect to such shares of Series A Preferred Stock shall on such redemption date cease and terminate, except only for the right of the Holders thereof to receive the amount payable in such redemption.
removal.
(b)    Withholding.
(c)     Each Holder shall be limited to three Demand Registrations under this Section 1.1 in any twelve-month period, and the Company shall not be obligated to file more than one Registration Statement within 120 days after the effective date of any Registration Statement filed by the Company; provided, however, that any Demand Registration shall not count towards this limit if the Registration Statement that is the subject of the Demand Registration (x) has not been declared effective by the SEC or (y) is not maintained effective for the period required pursuant to Section 1.2 (unless such Registration Statement again becomes effective or a Subsequent Registration 1
The rights of any particular Holder to cause the Company to register securities under Article I shall terminate with respect to such Holder upon the date upon which such Holder no longer holds any Registrable Securities.ARTICLE VMiscellaneousSection 5.1    Amendments and Waivers.
